Invasive Candidiasis
📧 Sign up to get email alerts when something new happens for Invasive Candidiasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-10Clinical Trial Results: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole [Phase 3]
A Phase 3 randomized, double-blind study comparing oral ibrexafungerp versus fluconazole following IV echinocandin for invasive candidiasis …
-
EMA approval · 2026-06-15EMA Authorised: Rezzayo (rezafungin) — Mundipharma GmbH
EMA authorised Rezzayo (rezafungin) for candidiasis and invasive candidiasis, marketed by Mundipharma GmbH.
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. [Phase 3]
Phase 3 trial update of fosmanogepix for treating candidemia and invasive candidiasis in adults; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Comparison of Uncomplicated Candidemia Therapy Duration in Children [NA]
This clinical trial is evaluating how long therapy should last for uncomplicated candidemia in pediatric patients, sponsored by Arkansas Chi…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation [Phase 3]
Phase 3 trial evaluating rezafungin versus standard antimicrobial prophylaxis to prevent invasive fungal diseases in adults undergoing allog…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-04-08EMA Authorised: Rezzayo (rezafungin) — Mundipharma GmbH
The European Medicines Agency authorized Rezzayo (rezafungin) from Mundipharma GmbH for the treatment of candidiasis, including invasive can…
-
FDA approval · 2026-02-19FDA Approved: VFEND — Supplemental Application (Roerig)
FDA approved a supplemental application for Vfend (voriconazole) submitted by Roerig.
-
CLINICAL_TRIALS trial_result · 2026-02-19Clinical Trial Update: Non-Conventional Microbiological Methods in the Diagnosis of Candidemia [NA]
A completed clinical trial evaluating non-conventional microbiological methods for the diagnosis of candidemia and invasive candidiasis.
-
CLINICAL_TRIALS withdrawal · 2026-02-19Clinical Trial Update: Phylogenetic Characteristics of Different Candida Species and Their Impact on the Clinical Picture of Patients With Invasive Candidiasis. What Has Changed During the COVID Pandemic?
A clinical trial investigating phylogenetic characteristics of Candida species and their impact on invasive candidiasis has been withdrawn.
-
FDA approval · 2026-01-21FDA Approved: MICAFUNGIN — Original Application (Hisun Pharmaceuticals USA, Inc.)
FDA approved Hisun Pharmaceuticals USA, Inc.'s original application for micafungin as a generic injectable antifungal. The approval covers u…
-
FDA approval · 2026-01-14FDA Approved: FLUCONAZOLE IN SODIUM CHLORIDE — Supplemental Application (Hospira, Inc.)
The FDA approved Hospira's supplemental application for Fluconazole in Sodium Chloride (intravenous formulation), adding this generic IV flu…
-
CLINICAL_TRIALS trial_result · 2025-12-19Clinical Trial Update: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole [Phase 3]
Phase 3, randomized, double-blind trial evaluating ibrexafungerp vs fluconazole after IV echinocandin for invasive candidiasis and candidemi…
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: Pharmacokinetics of Micafungin in Patients of Intensive Care Units [Phase 4]
Phase 4 pharmacokinetic study of micafungin in ICU patients with invasive candidiasis has completed.
-
CLINICAL_TRIALS trial_result · 2025-09-08Clinical Trial Update: Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis [NA]
A completed clinical trial evaluating hepatosplenic candidiasis using PET scans and immune response analysis in patients with invasive candi…
-
FDA approval · 2025-07-23FDA Approved: MICAFUNGIN — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Micafungin (Hikma Pharmaceuticals USA Inc.), leading to changes/updates approved for this antifu…
-
FDA approval · 2025-07-18FDA Approved: CASPOFUNGIN ACETATE — Original Application (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.)
The FDA approved Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.'s caspofungin acetate as an original generic application (ANDA) for mark…
-
CLINICAL_TRIALS research · 2025-06-05Clinical Trial Update: Invasive Candidiasis in Critical Care
A clinical trial evaluating treatment for invasive candidiasis in critical care is currently recruiting. The study is sponsored by Universit…
-
CLINICAL_TRIALS trial_result · 2025-04-09Clinical Trial Update: A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus [Phase 3]
Phase 3 trial of ABCD for Injection for invasive candidiasis and invasive aspergillosis has completed.
-
FDA approval · 2025-04-03FDA Approved: MICAFUNGIN — Original Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved Glenmark's original ANDA for generic micafungin for the treatment of invasive candidiasis, candidemia, esophageal candidiasis, …
-
CLINICAL_TRIALS research · 2025-02-28Clinical Trial Update: Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants [Phase 4]
A Phase 4 clinical trial update evaluating posaconazole pharmacokinetics in patients receiving chemotherapy or stem cell transplants; recrui…
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment [Phase 3]
Phase 3 study assessing ibrexafungerp in patients with invasive and mucocutaneous fungal diseases refractory to or intolerant of standard tr…
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia [Phase 4]
A Phase 4 trial evaluating micafungin for invasive candidiasis or candidemia was terminated.
-
CLINICAL_TRIALS trial_result · 2024-11-19Clinical Trial Update: A Study to Evaluate Pre-emptive Treatment for Invasive Candidiasis in High Risk Surgical Subjects [Phase 2]
Phase 2 trial by Astellas evaluating pre-emptive treatment for invasive candidiasis in high-risk surgical subjects has completed.
-
CLINICAL_TRIALS trial_result · 2024-11-18Clinical Trial Update: Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug [Phase 1]
Phase 1 study of Mycamine in children to evaluate safety and drug blood levels in fungal infections; the trial has completed.
-
CLINICAL_TRIALS research · 2024-11-18Clinical Trial Update: A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis [Phase 2]
A Phase 2 clinical trial is evaluating intravenous HRS9432 for the treatment of candidemia and/or invasive candidiasis and is currently recr…